Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06602219 · ClinicalTrials.gov registry record · Phase 2
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
A Phase 2 study, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT06602219: Completed Phase 2 study, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
NCT06602219 is a Phase 2 study that has completed, run by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. The registered enrollment target is 222 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06602219, a Phase 2 study, has completed, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Primary Outcome
Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity sc
Interventions
- DRUG Placebo
- DRUG LY4100511
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 2 |
What the finished NCT06602219 record still lists
NCT06602219 is an interventional study that assigns participants to a tested intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06602219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06602219 about?
NCT06602219 is a clinical study titled "A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis". The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT06602219?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2024-10-25. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT06602219?
The interventions under investigation include: Placebo (DRUG), LY4100511 (DRUG).
Who is sponsoring clinical trial NCT06602219?
This trial is sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06602219's enrollment target sits among peer trials
222 274th of 2000 higher than 1,726 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
- NCT05605574 · 222 participants · NA
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI